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226The use of aspirin in the secondary
prevention of patients with acute
coronary syndromes (ACS) traces
a long history that began with the
landmark ISIS-2 (Second Inter-
national Study of Infarct Survival)
study in 1988, which reported that
160 mg/day of aspirin within
24 h of presentation signiﬁcantly
reduced re-infarction and non-
fatal stroke without a signiﬁcant
increase in cerebral hemorrhage
(1). Demonstration of the efﬁ-
cacy of aspirin was subsequently
extended across the entire spec-
trum of ACS, from ST-segment
elevation myocardial infarction
(MI) to unstable angina/non–
ST-segment elevation myocardial
infarction (NSTEMI) (2–4). The
dose of aspirin used in thesepreliminary studies, however, was highly variable and ranged
from 75 to 325 mg, leaving many unanswered questions
about what the optimal daily dose of aspirin should be after
ACS (5).
The PLATO (Platelet Inhibition and Patient Outcomes)
trial randomly assigned 18,624 patients with ACS to receive
either the potent P2Y12 receptor antagonist ticagrelor or the
ﬁrst-generation thienopyridine clopidogrel, in addition to
aspirin, with the dose of aspirin left to the discretion of the
local investigator. This trial demonstrated a beneﬁt of tica-
grelor compared with clopidogrel in the reduction of recur-
rent cardiovascular events (6). Within the trial, however, an
apparent decreased efﬁcacy of ticagrelor was noted in North
American subjects (7). Subsequent analysis of this ﬁnding
suggested that it might have been related to the reduced
efﬁcacy of ticagrelor in combination with the higher doses of
aspirin more commonly prescribed in North America (7).
Based on these ﬁndings, the US Food and Drug Adminis-
tration recommended that ticagrelor be used only in combi-
nation with low doses of aspirin (i.e., 75 to 100 mg/day) (8).
Like ticagrelor, prasugrel is a more potent P2Y12 receptor
antagonist than clopidogrel. The goal of the current study
was to determine whether the dose of aspirin affected the
comparison between prasugrel and aspirin in the TRITON-
TIMI 38 (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition With Prasu-
grel–Thrombolysis In Myocardial Infarction 38) trial (9).Methods
Patient population and treatments. TRITON–TIMI
38 was a multicenter, double-blind trial of patients with
ACS, including high-risk unstable angina/NSTEMI and
ST-segment elevation MI with planned percutaneous coro-
nary intervention (PCI), who were randomized to receiveeither prasugrel or clopidogrel. All patients randomized into
TRITON–TIMI 38 with previously published inclusion and
exclusion criteria (10) who were still alive and free from MI,
stroke, coronary artery bypass grafting (CABG), or Throm-
bolysis In Myocardial Infarction (TIMI) major bleed at the
time of discharge and had information on discharge aspirin
dose were included in our substudy.
All patients in this study were treated with aspirin plus
a thienopyridine. The thienopyridine was randomly assigned
as either prasugrel (60-mg loading dose, 10 mg daily) or
clopidogrel (300-mg loading dose, 75 mg daily) for up to 15
months in a double-blind fashion; study drug could be
administered on presentation with ST-segment elevation MI
for primary PCI and at the time coronary anatomywas known
to be suitable for PCI in all other subjects. The dose of aspirin
selected at the time of PCI, during hospitalization, and at
discharge was left to the discretion of the treating physician,
with a loading dose suggested for those not previously taking
aspirin and a recommended (but not mandated) maintenance
dose of 75 to 100 mg. Dose adjustments were permitted for
aspirin during the study period.
Outcomes. In this analysis, we report the relationship of
randomized treatment arm (prasugrel vs. clopidogrel) and
discharge aspirin dose to the primary efﬁcacy and safety
outcomes of the overall trial up to a follow-up time of 450
days, including the primary composite endpoint of the trial
(cardiovascular death, MI, or stroke [CVD/MI/stroke]).
Deﬁnite or probable stent thrombosis, as deﬁned by the
Academic Research Consortium, was also examined in the
trial as a secondary outcome. Key safety endpoints included
non–CABG-related TIMI major and minor bleeding as well
as non-CABG gastrointestinal bleeding. All efﬁcacy and
safety outcomes were adjudicated by a blinded clinical events
committee by using prespeciﬁed deﬁnitions (10).
Substudy population and classiﬁcation. To minimize
confounding with respect to aspirin dose at discharge, we
excluded patients from the overall study cohort who expe-
rienced any component of the primary endpoint (CVD/MI/
stroke), CABG, or bleeding event (n ¼ 873) during the
index hospitalization; those with deﬁnite/probable stent
thrombosis (n ¼ 8) during index hospitalization; and those
missing aspirin dose information before or at hospital
discharge (n ¼ 53). Based on the discharge dose of aspirin,
all remaining patients (n ¼ 12,674) were classiﬁed as
receiving low-dose (<150 mg) or high-dose (150 mg)
aspirin. As a sensitivity analysis, we also report the rela-
tionship between prasugrel versus clopidogrel and aspirin
dose and efﬁcacy and safety outcomes, with low-dose aspirin
deﬁned as 100 mg and high-dose deﬁned as >100 mg, as
previously deﬁned (5).
Statistical methods. The baseline characteristics of low-
and high-dose aspirin groups were compared by using the
Wilcoxon rank sum test for continuous variables and the
chi-square test for categorical variables. Using a univariate
Cox proportional hazards regression model, we calculated
hazard ratios (HRs) and 95% conﬁdence intervals (CIs) to
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227compare the efﬁcacy and safety of prasugrel versus clopi-
dogrel within the low-dose and high-dose aspirin groups
and assessed the interaction between aspirin dose group and
clinical efﬁcacy of prasugrel. In these analyses, an interaction
was considered statistically signiﬁcant if the p value
was <0.05. Multivariable logistic regression was derived to
study the association between baseline characteristics and
maintenance aspirin dose, with the low-dose aspirin groups
serving as the reference group. Kaplan-Meier rates and
curves were reported through 450 days of follow-up. To
adjust for baseline differences, a propensity score was
calculated by using forward selection, adding in all baseline
characteristics with p < 0.20, and propensity score–adjusted
Cox models were generated. Randomization group was
included as a covariate in these propensity score–adjusted
Cox models, and we assessed the association of high-dose
versus low-dose aspirin with clinical outcomes. Therefore,
the relationship between aspirin dose and outcomes was
adjusted for by using both the propensity score and the
randomization group. All analyses reported in the current
paper were investigator-driven and performed independently
by the TIMI Study Group by using STATA/SE version
12.1 (Stata Corp, College Station, Texas).
Results
Of the 12,674 patients eligible for our analysis, 7,606 (60%)
received low-dose aspirin (<150 mg) and 5,068 (40%)
received high-dose aspirin (150 mg) at time of discharge.
Within both groups, individuals were evenly balanced
between the randomized treatment arms: in the low-dose
group, 3,831 (50.4%) were randomized to receive prasugrel
and 3,775 (49.6%) were randomized to receive clopidogrel;
in the high-dose group, 2,549 (50.3%) were randomized to
receive prasugrel and 2,519 (49.7%) were randomized to
receive clopidogrel (p ¼ 0.94). When assessed over time, the
majority of patients remained within the same category (low
or high) as their discharge dose during the remainder of
follow-up (30 days 94%; 90 days 92%; 180 days 90%; 270
days 89%; 360 days 87%).
There were several differences in baseline characteristics
between aspirin dose groups (Table 1). Notably, in the
TRITON–TIMI 38 trial, high-dose aspirin was used more
frequently in younger patients, those with unstable angina/
NSTEMI as an index event, those with previous MI, and in
patients who had a drug-eluting stent placed during PCI. In
addition, there was marked geographical variation with
respect to aspirin dosing, with 66% of patients in North
America receiving high-dose aspirin compared with only
28% in other countries (p < 0.001) (Fig. 1). Within each
stratum of aspirin dosing, baseline characteristics were
generally well balanced between prasugrel versus clopidogrel
(Online Table 1).
Independent correlates of discharge aspirin dose
selection. After adjustment, several clinical factors emerged
as independent correlates of aspirin dosing. As depicted inFigure 2, the strongest correlate of high-dose aspirin use was
geographical region, with an odds ratio (OR) of 5.19 (95%
CI: 4.72 to 5.70; p < 0.001) for North America versus other
countries worldwide. Additional independent characteristics
associated with high-dose aspirin use included previous PCI
(OR: 1.18 [95% CI: 1.03 to 1.35], p ¼ 0.015), systolic blood
pressure (OR: 1.03 per 10-mmHg increase [95% CI: 1.02 to
1.05], p < 0.001), and use of aspirin at randomization (OR
1.37 [95% CI: 1.07 to 1.76], p ¼ 0.013). Factors associated
with use of low-dose aspirin were age 75 years (OR: 0.87
[95% CI: 0.77 to 0.98], p ¼ 0.023), white race (OR: 0.76
[95% CI: 0.65 to 0.88], p< 0.001), higher baseline heart rate
(OR: 0.96 per 10 beats/min increase in heart rate [95% CI:
0.93 to 0.99], p ¼ 0.004), and use of a glycoprotein IIb/IIIa
inhibitor (OR: 0.87 [95% CI: 0.80 to 0.95], p ¼ 0.002),
bivalirudin (OR: 0.73 [95% CI: 0.58 to 0.91], p ¼ 0.006), or
another nonheparin antithrombin agent (OR: 0.90 [95% CI:
0.82 to 1.00], p ¼ 0.04) during PCI.
Prasugrel versus clopidogrel stratiﬁed according to
aspirin dose group: efﬁcacy and safety endpoints. There
was no modiﬁcation of the clinical effect of prasugrel versus
clopidogrel based on discharge aspirin dose with respect to
the primary efﬁcacy endpoint (HRCVD/MI/stroke ¼ 0.78 [95%
CI: 0.64 to 0.95] for aspirin<150mg;HRCVD/MI/stroke¼ 0.87
[95% CI: 0.69 to 1.10] for aspirin 150 mg; p value for
interaction ¼ 0.48) (Fig. 3A) or the primary safety endpoint
(HRTIMI major bleeding ¼ 1.47 [95% CI 0.97 to 2.21] for
aspirin<150 mg; HRTIMI major bleeding¼ 1.58 [95% CI: 0.92
to 2.69] for aspirin 150 mg; p value for interaction ¼ 0.84)
(Fig. 3B). Although the only comparison that achieved
statistical signiﬁcance for the superiority of prasugrel over
clopidogrel was the primary efﬁcacy endpoint of CVD/MI/
stroke in the low-dose aspirin group, the point estimates
remain directionally consistent with the results of the overall
TRITON–TIMI38 trial. Similarly, for both the high- or low-
dose aspirin groups, the pattern of prasugrel effects compared
with clopidogrel (fewer primary and secondary endpoint
events and higher bleeding) with directionally preserved point
estimates were similar to the parent trial, although not all
comparisons achieved statistical signiﬁcance (Fig. 4). Patients
randomized to receive prasugrel had higher bleeding rates
than patients randomized to receive clopidogrel, regardless of
the dose of aspirin used. These results were also consistent in
sensitivity analyses when the aspirin dose cutoff of 100 mg
was used to deﬁne the low-dose group or when a cutoff
of <150 mg was used and in-hospital endpoint events were
included in the analysis. In addition, when analyzed within
aspirin dose groups, the safety and efﬁcacy relationship of
prasugrel vs. clopidogrel was maintained (Online Table 2).
Discussion
In this analysis of the TRITON–TIMI 38 trial of ACS
patients, we made several observations. First, we added to
the previous body of literature that there is signiﬁcant global
variation with respect to discharge aspirin dose. In
Table 1
Baseline Characteristics of Patients Receiving Low-Dose Aspirin (<150 mg) Versus




(n ¼ 5,068) p Value
Presenting characteristics
Age (yrs) 61 (53–70) 60 (52–68) <0.001
Age 75 yrs (%) 13.8 11.8 <0.001
Weight (kg) 80 (72–91) 83 (74–95) <0.001
Body mass index (kg/m2) 27.7 (25–30.8) 28.1 (25.4–31.8) <0.001
Male (%) 74.3 74.2 0.89
White race (%) 94.6 89.5 <0.001
North America (%) 18.0 52.2 <0.001
UA/NSTEMI (%) 72.9 76.6 <0.001
SBP (mm Hg) 130 (120–149) 132 (118–150) 0.74
DBP (mm Hg) 80 (70–86) 77 (68–86) <0.001
Heart rate (beats/min) 70 (62–80) 70 (61–80) <0.001
Creatinine clearance (ml/min) 97.5 (75.6–123.8) 103.2 (79.9–130.6) <0.001
Medical history (%)
Hypertension 63.4 65.0 0.065
Hyperlipidemia 53.3 59.6 <0.001
Diabetes 23.0 23.7 0.37
Previous MI 16.6 19.3 <0.001
Previous stroke/TIA 3.6 4.0 0.27
Current tobacco use 37.9 39.6 0.053
In-hospital treatments (%)
DES during PCI 38.7 60.2 <0.001
Multivessel PCI 13.7 14.8 0.094
Antithrombin used <0.001




Use of GPIIb/IIIa inhibitor in index hospitalization 50.9 58.7 <0.001
Timing of PCI load <0.001
Pre-PCI 27.0 22.4
During PCI 72.2 76.6
Post-PCI 0.74 1.05
ACE inhibitor/ARB 77.3 72.9 <0.001
Beta-blocker 87.5 89.9 <0.001
Statin 93.3 91.2 <0.001
Calcium channel blocker 17.1 17.7 0.38
Randomized to receive prasugrel 50.4 50.3 0.94
Values are median (interquartile range) or %.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; DBP ¼ diastolic blood pressure; DES ¼ drug-eluting stent; GPIIb/IIIa ¼
glycoprotein IIb/IIIa; LMWH ¼ low-molecular-weight heparin; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction;
PCI ¼ percutaneous coronary intervention; SBP ¼ systolic blood pressure; TIA ¼ transient ischemic stroke; UA ¼ unstable angina.
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228TRITON–TIMI 38, higher-dose aspirin was used much
more frequently in North America compared with the rest of
the world, which more frequently prescribed lower-dose
aspirin. Second, our major novel ﬁnding was that there
seems to be no signiﬁcant interaction between discharge
aspirin dose and the clinical effect of prasugrel versus clo-
pidogrel. Prasugrel was statistically superior to clopidogrel in
reducing the composite primary endpoint of CVD/MI/
stroke and directionally lower for stent thrombosis in the
low dose aspirin group, with a directionally consistent
improvement that did not achieve statistical signiﬁcance in
the high-dose aspirin group for the primary endpoint and for
stent thrombosis. Similarly, prasugrel resulted in a higherbleeding rate, including TIMI major non-CABG bleeding
and TIMI major/minor non-CABG bleeding, compared
with clopidogrel, regardless of discharge aspirin dose.
The geographical variation of aspirin use after ACS in our
study conﬁrms a practice pattern similar to previous studies,
including the PLATO study, which also demonstrated
signiﬁcantly more high-dose aspirin use in North America
(7). Even after adjustment for baseline differences in patient
characteristics and risk proﬁles, geographical region persisted
as an independent correlate of aspirin dosing. The expla-
nation for this disparity is unclear, but it is likely a result of
historical prescribing practices and guidelines that differ
according to country (5,7,11,12).
Figure 1
Discharge ASA Dose According to
Geographical Region
Geographical variation with respect to low- versus high-dose aspirin (ASA) in
(A) North America and (B) other countries (p < 0.001).
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229Until recently (including during the conduct of
TRITON–TIMI 38), the American College of Cardiology/
American Heart Association ACS guidelines had main-
tained recommendations for higher-dose aspirin in the
setting of recent coronary stents, particularly drug-eluting
stents (13). In 2011, an update to these guidelines for the
management of ACS revised the recommendation to change
the discharge aspirin dose from high dose to low dose (14).
Aspirin exhibits dose-dependent pharmacology. At low
daily doses (w100 mg), it selectively acetylates cyclo-
oxygenase (COX)-1, leading to irreversible inhibition of thisFigure 2 Clinical Correlates of Discharge ASA Dose
Independent clinical correlates of low- and high-dose ASA (N ¼ 12,048) are depicted with p
features more likely in patients taking high-dose ASA. bpm ¼ beats per minute; GPIIb/III
coronary intervention; SBP ¼ systolic blood pressure; other abbreviations as in Figure 1.enzyme and decreased production of its downstream medi-
ators, which are implicated in platelet aggregation and
vascular reactivity and vasoconstriction; therefore, inhibiting
the upstream COX-1 enzyme results in an antiplatelet and
vasodilatory effect (15). At doses typically much higher than
those used in ACS (650 mg to 4 g), however, aspirin can
also inhibit COX-2, another isoform of this enzyme that is
inducible and involved in pathological processes, including
inﬂammation and pain, and potentially more complete
inhibition of COX-1 (16,17). However, there remains
a continuum and dose-response relationship between these
lower and higher doses of aspirin. Therefore, higher doses
may improve efﬁcacy but may also lead to increased bleeding
(18) by depleting gastroprotective prostacyclins. In addition,
aspirin impairs adenosine diphosphate (ADP) release and
ADP-dependent platelet aggregation, and its effects on
platelets are dose dependent and irreversible (18). Therefore,
higher doses of aspirin also have the potential for increased
drug–drug interactions with respect to the ADP receptor
antagonists (clopidogrel, prasugrel, and ticagrelor).
Our results do not support any interaction (favorable or
unfavorable) between prasugrel and aspirin dose. There are
many possible explanations for our ﬁndings in the context of
the PLATO study, in which ticagrelor was associated with
worse outcomes when given concurrently with high-dose
aspirin (7). Although both ticagrelor and prasugrel act via
the potent inhibition of the P2Y12 ADP receptor, theoint estimates and 95% conﬁdence intervals. An odds ratio (OR) >1 indicates clinical
a ¼ glycoprotein IIb/IIIa; HR ¼ heart rate; NA ¼ North America; PCI ¼ percutaneous
Figure 3 Time to Event Curves for Prasugrel Versus Clopidogrel According to Discharge ASA Dose
Kaplan-Meier time to event curves for prasugrel versus clopidogrel for (A) cardiovascular death (CVD)/myocardial infarction (MI)/stroke and (B) Thrombolysis in Myocardial
Infarction (TIMI) major non–coronary artery bypass grafting bleeding with adjusted hazard ratios (Adj. HR) and 95% conﬁdence intervals within each ASA dosing strata; other
abbreviation as in Figure 1.
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230mechanism of action of the 2 drugs is slightly different.
Ticagrelor binds reversibly, allowing for the potential for
greater drug–drug interaction with the irreversible action of
aspirin on platelets. However, it is also possible that there
might not be a true pharmacological interaction between
ticagrelor and aspirin dose, and the interaction previously
observed with ticagrelor and high-dose aspirin may have
occurred by chance due to a small patient subgroup (19).
Our ﬁndings are relevant with respect to the possible
interaction between the ﬁrst-generation thienopyridine
clopidogrel and aspirin. In the CURRENT OASIS-7
(Clopidogrel and Aspirin Optimal Dose Usage to Reduce
Recurrent Events–Seventh Organization to Assess Strate-
gies in Ischemic Syndromes) trial, 25,086 ACS patients
undergoing PCI were randomly assigned in a 2  2 factorial
design to receive either a lower dose (75 to 100 mg) ora higher dose (300 to 325 mg) of aspirin with either
a standard or a double dose of clopidogrel for 7 days (20).
There was a signiﬁcant interaction between high-dose
aspirin and high-dose clopidogrel, suggesting that high-
dose clopidogrel was more effective than standard-dose
clopidogrel in the setting of high-dose aspirin. Based on
the PLATO and CURRENT-OASIS 7 ﬁndings, contro-
versy exists as to whether more intensive antiplatelet therapy
(including ticagrelor and high-dose clopidogrel) has altered
efﬁcacy in the setting of high-dose aspirin. In TRITON-
TIMI 38, prasugrel remains more effective than standard-
dose clopidogrel at all doses of aspirin, and there is no
interaction (in either direction) with aspirin and prasugrel
for the primary or secondary efﬁcacy endpoint.
The safety ﬁndings in our analysis also reﬂect no effect
modiﬁcation of discharge aspirin dose on the clinical
Figure 4 Key Endpoints Stratiﬁed According to ASA Dose
Univariate hazard ratios and 95% conﬁdence intervals for prasugrel versus clopidogrel and key endpoints by ASA dosing. CABG ¼ coronary artery bypass grafting; p-int ¼ p value
for interaction; other abbreviations as in Figures 1 and 3.
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231bleeding observed with prasugrel versus clopidogrel. This
ﬁnding is consistent across key bleeding endpoints,
including TIMI major non-CABG bleeding, TIMI minor
non-CABG bleeding, and TIMI major non-CABG
bleeding (although only TIMI major/minor bleeding
achieved statistical signiﬁcance in both groups). In the
CURE (Clopidogrel in Unstable Angina to Prevent
Recurrent Events) study, which randomized patients with
ACS to receive aspirin plus placebo versus aspirin plus
clopidogrel, there was a higher bleeding risk observed with
higher-dose aspirin, with or without clopidogrel, suggesting
that bleeding may be additive when high-dose aspirin
and clopidogrel are used simultaneously (21). In the
CURRENT-OASIS 7 trial, there were no signiﬁcant
differences with respect to TIMI major bleeding or inter-
action between the aspirin dose and the higher dose of
clopidogrel with respect to bleeding. Our study also found
no such interaction, and prasugrel continued to confer
a higher risk of bleeding than clopidogrel, regardless of
whether low- or high-dose aspirin was used.
Study limitations. Aspirin dose at discharge is a post-
randomization variable and therefore subject to confounding
by indication, selection, and survival bias. As a result, we
focused on the results of the randomized prasugrel versus
clopidogrel comparison for our analysis in relation to
discharge aspirin doses rather than comparing the efﬁcacy
and safety of aspirin doses directly. Because we analyzed
subgroups based on discharge aspirin doses, because weexcluded from our analysis those patients who had an in-
hospital endpoint or bleeding event, and because there
may be differences in in-hospital treatment, we cannot
exclude the possibility of an early interaction or that
(although unlikely given directional consistency) an inter-
action could have been observed had the individual
subgroups been larger. In addition, there may have been
some variation in aspirin dosing during the study due to
adverse effects or changes in a patient’s clinical status. To
address this limitation, we were able to demonstrate that
a very high percentage of patients remained within the same
aspirin dose group throughout the duration of the study as at
the time of discharge. Finally, although we have accounted
for baseline differences in our observational study through
multivariable adjustment and propensity matching, residual
unmeasured confounding may still exist.
Conclusions
These results provide contemporary evidence within the
context of a trial of patients with moderate- to high-risk
ACS treated with potent dual antiplatelet therapy that
discharge aspirin dose does not modulate clinical outcomes
of patients treated with prasugrel compared with clopidogrel.
Notably, unlike the potential effect reported with high-dose
aspirin and ticagrelor, there seems to be no clinically
meaningful interaction of maintenance dose of aspirin with
prasugrel.
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